ICML 2017 | Overview of classical therapies for follicular lymphoma

Andrew Lister

Andrew Lister, MD, from Barts Cancer Institute, London, UK, gives an overview of the session he chaired, ‘Classical therapies for follicular lymphoma’ at the International Conference on Malignant Lymphoma (ICML) 2017, in Lugano Switzerland. Recent developments in the treatment of follicular lymphoma (FL) include rituximab. PET scanning in stage 1 and 2 FL is useful when deciding whether to treat with radiation, or to watch and wait, however, it is generally agreed that radiation would be the treatment of choice. A recent trial, whereby patients were randomly allocated to receive either radiation alone, or radiation with either CVP or R-CVP. Although the results of this trial showed an advantage in terms of progression free survival, there was no change in overall survival. He states that the results of this trial emphasised the fact that trials in this area are feasible.

Share this video